A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

Cancer

Volumn 117, Issue 6, 2011, Pages 1253-1261

  Sekeres, Mikkael A ^a   MacIejewski, Jaroslaw P ^a   Erba, Harry P ^b   Afable, Manuel ^a   Englehaupt, Ricki ^a   Sobecks, Ronald ^a   Advani, Anjali ^a   Seel, Sherry ^a   Chan, Josephine ^a   Kalaycio, Matt E ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

acute myeloid leukemia; arsenic trioxide; clinical trial; gemtuzumab ozogamicin; myelodysplastic syndromes

Indexed keywords

ARSENIC TRIOXIDE; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CHILL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ECCHYMOSIS; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; INSOMNIA; LENGTH OF STAY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PETECHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REFRACTORY ANEMIA WITH EXCESS BLASTS; RIGOR; THROMBOCYTOPENIA; TREATMENT DURATION; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; OXIDES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 79952375520     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25686     Document Type: Article

References (29)

1. Ma X, Does M, Raza A, Mayne ST., Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109: 1536-1542. (Pubitemid 46595689)
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-199. (Pubitemid 12073508)
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088. (Pubitemid 27132124)
4. Vardiman J, Thiele J, Arber D, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
5. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-1551.
6. Sugimoto K, Hirano N, Toyoshima H, et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood. 1993; 81: 3022-3026. (Pubitemid 23162121)
7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999; 10: 1419-1432. (Pubitemid 30017051)
8. Vallespi T, Torrabadella M, Julia A, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol. 1985; 61: 83-92. (Pubitemid 15225444)
9. Foucar K, Langdon RM, Armitage JO, Olson DB, Carroll TJ,. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer. 1985; 56: 553-561. (Pubitemid 15035583)
10. Economopoulos T, Stathakis N, Foudoulakis A, et al. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur J Haematol. 1987; 38: 338-344.
11. Kerkhofs H, Hermans J, Haak HL, Leeksma CH., Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol. 1987; 65: 73-81. (Pubitemid 17234315)
12. Appelbaum FR., Antibody-targeted therapy for myeloid leukemia. Semin Hematol. 1999; 36 (4 suppl 6): 2-8. (Pubitemid 29489654)
13. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323-3329.
14. Rossi G, Pelizzari AM, Bellotti D, Tonelli M, Barlati S., Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000; 14: 636-641. (Pubitemid 30195454)
15. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110: 4385-4395. (Pubitemid 351377805)
16. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232.
17. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001; 19: 3244-3254. (Pubitemid 32591442)
18. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999; 93: 3678-3684. (Pubitemid 29249814)
19. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89: 3345-3353.
20. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88: 1052-1061. (Pubitemid 26333331)
21. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000; 96: 1525-1530. (Pubitemid 30658486)
22. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24: 2465-2471. (Pubitemid 46630623)
23. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006; 24: 2456-2464. (Pubitemid 46630622)
24. Vardiman JW, Harris NL, Brunning RD., The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2302.
25. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336. (Pubitemid 35429670)
26. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425. (Pubitemid 44061337)
27. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649. (Pubitemid 46594039)
28. Faderl S, Garcia-Manero G, Ravandi F, et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). ASH Annual Meeting Abstracts. 2008;112:222-. Available at:.
29. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 1114-1124. (Pubitemid 46435390)